362 related articles for article (PubMed ID: 33929500)
1. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations.
Heuser M; Heida B; Büttner K; Wienecke CP; Teich K; Funke C; Brandes M; Klement P; Liebich A; Wichmann M; Neziri B; Chaturvedi A; Kloos A; Mintzas K; Gaidzik VI; Paschka P; Bullinger L; Fiedler W; Heim A; Puppe W; Krauter J; Döhner K; Döhner H; Ganser A; Stadler M; Hambach L; Gabdoulline R; Thol F
Blood Adv; 2021 May; 5(9):2294-2304. PubMed ID: 33929500
[TBL] [Abstract][Full Text] [Related]
2. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
3. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
Chen W; Huang J; Zhao Y; Huang L; Yuan Z; Gu M; Xu X; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Bao C; Huang X; Zheng Z; Huang H; Hu X; Zhao Y
J Transl Med; 2024 Apr; 22(1):410. PubMed ID: 38689269
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
Kim HJ; Kim Y; Kang D; Kim HS; Lee JM; Kim M; Cho BS
Blood Cancer J; 2021 Jun; 11(6):109. PubMed ID: 34088902
[TBL] [Abstract][Full Text] [Related]
5. Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
Hourigan CS; Dillon LW; Gui G; Logan BR; Fei M; Ghannam J; Li Y; Licon A; Alyea EP; Bashey A; Deeg HJ; Devine SM; Fernandez HF; Giralt S; Hamadani M; Howard A; Maziarz RT; Porter DL; Scott BL; Warlick ED; Pasquini MC; Horwitz ME
J Clin Oncol; 2020 Apr; 38(12):1273-1283. PubMed ID: 31860405
[TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
7. Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation.
Wienecke CP; Heida B; Venturini L; Gabdoulline R; Krüger K; Teich K; Büttner K; Wichmann M; Puppe W; Neziri B; Reuter M; Dammann E; Stadler M; Ganser A; Hambach L; Thol FR; Heuser M
Blood; 2024 Apr; ():. PubMed ID: 38669617
[TBL] [Abstract][Full Text] [Related]
8. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
[TBL] [Abstract][Full Text] [Related]
9. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
[TBL] [Abstract][Full Text] [Related]
10. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.
Delsing Malmberg E; Johansson Alm S; Nicklasson M; Lazarevic V; Ståhlman S; Samuelsson T; Lenhoff S; Asp J; Ehinger M; Palmqvist L; Brune M; Fogelstrand L
Leuk Lymphoma; 2019 Feb; 60(2):409-417. PubMed ID: 30068244
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.
Tsai CH; Tang JL; Tien FM; Kuo YY; Wu DC; Lin CC; Tseng MH; Peng YL; Hou MF; Chuang YK; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
Blood Adv; 2021 May; 5(10):2456-2466. PubMed ID: 33999144
[TBL] [Abstract][Full Text] [Related]
13. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
14. Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia.
Wong ZC; Dillon LW; Hourigan CS
Best Pract Res Clin Haematol; 2023 Jun; 36(2):101468. PubMed ID: 37353292
[TBL] [Abstract][Full Text] [Related]
15. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
[TBL] [Abstract][Full Text] [Related]
16. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML).
Patkar N; Kakirde C; Shaikh AF; Salve R; Bhanshe P; Chatterjee G; Rajpal S; Joshi S; Chaudhary S; Kodgule R; Ghoghale S; Deshpande N; Shetty D; Khizer SH; Jain H; Bagal B; Menon H; Khattry N; Sengar M; Tembhare P; Subramanian P; Gujral S
Leukemia; 2021 May; 35(5):1392-1404. PubMed ID: 33558666
[TBL] [Abstract][Full Text] [Related]
18. Detection of measurable residual disease may better predict outcomes than mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
Wang J; Lu R; Wu Y; Jia J; Gong L; Liu X; Lu S; Wang Y; Yan C; Liu K; Zhang X; Xu L; Jiang Q; Zhao X; Shi H; Lai Y; Huang X; Ruan G; Jiang H
Br J Haematol; 2020 Aug; 190(4):533-544. PubMed ID: 32090321
[TBL] [Abstract][Full Text] [Related]
19. Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML.
Murdock HM; Kim HT; Denlinger N; Vachhani P; Hambley B; Manning BS; Gier S; Cho C; Tsai HK; McCurdy S; Ho VT; Koreth J; Soiffer RJ; Ritz J; Carroll MP; Vasu S; Perales MA; Wang ES; Gondek LP; Devine S; Alyea EP; Lindsley RC; Gibson CJ
Blood; 2022 Jun; 139(24):3546-3557. PubMed ID: 35286378
[TBL] [Abstract][Full Text] [Related]
20. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
Kim JJ; Jang JE; Lee HA; Park MR; Kook HW; Lee ST; Choi JR; Min YH; Shin S; Cheong JW
Ann Lab Med; 2023 Jul; 43(4):328-336. PubMed ID: 36843401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
